Phenindione

Suppliers

Names

[ CAS No. ]:
83-12-5

[ Name ]:
Phenindione

[Synonym ]:
2-PHENYL-1,3-INDANDIONE
2-phenylindene-1,3-dione
EINECS 201-454-4
MFCD00003782

Chemical & Physical Properties

[ Density]:
1.343g/cm3

[ Boiling Point ]:
243.3 °C (0.3 mmHg)

[ Melting Point ]:
144-148 °C(lit.)

[ Molecular Formula ]:
C15H10O2

[ Molecular Weight ]:
222.23900

[ Flash Point ]:
208 °C

[ Exact Mass ]:
222.06800

[ PSA ]:
34.14000

[ LogP ]:
2.84940

[ Index of Refraction ]:
1.703

[ Storage condition ]:
2-8°C

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NK6125000
CHEMICAL NAME :
1,3-Indandione, 2-phenyl-
CAS REGISTRY NUMBER :
83-12-5
LAST UPDATED :
199512
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C15-H10-O2
MOLECULAR WEIGHT :
222.25
WISWESSER LINE NOTATION :
L56 BV DV CHJ CR

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
42500 ug/kg/17D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - interstitial nephritis Kidney, Ureter, Bladder - urine volume decreased
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,1655,1963
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
48 mg/kg/27D-I
TOXIC EFFECTS :
Blood - other changes Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
NZMJAX New Zealand Medical Journal. (New Zealand Medical Assoc., P.O. Box 156, Wellington, New Zealand) V.1- 1900- Volume(issue)/page/year: 57,283,1958
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
22 mg/kg/17D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Kidney, Ureter, Bladder - interstitial nephritis Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 52,706,1960
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
90 mg/kg/27D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Skin and Appendages - dermatitis, allergic (after systemic exposure)
REFERENCE :
CMAJAX Canadian Medical Association Journal. (Canadian Medical Assoc., POB 8650, Ottawa, ON K1G 0G8, Canada) V.1- 1911- Volume(issue)/page/year: 77,1028,1957
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1683 mg/kg/31D-I
TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,920,1963
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
163 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 9,519,1974
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
190 mg/kg
TOXIC EFFECTS :
Behavioral - rigidity (including catalepsy) Behavioral - muscle contraction or spasticity
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 16,34,1961
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
175 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
SMWOAS Schweizerische Medizinische Wochenschrift. (Schwabe & Co., Steintorst 13, 4010 Basel, Switzerland) V.50- 1920- Volume(issue)/page/year: 90,213,1960
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PHARAT Pharmazie. (VEB Verlag Volk und Gesundheit, Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1946- Volume(issue)/page/year: 27,520,1972
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
140 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DIPHAH Dissertationes Pharmaceuticae. (Warsaw, Poland) V.1-17, 1949-65. For publisher information, see PJPPAA. Volume(issue)/page/year: 8,289,1956
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
130 mg/kg
TOXIC EFFECTS :
Behavioral - rigidity (including catalepsy) Behavioral - muscle contraction or spasticity
REFERENCE :
THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 16,34,1961 *** REVIEWS *** TOXICOLOGY REVIEW AJMEAZ American Journal of Medicine. (Technical Pub., 875 Third Ave., New York, NY 10022) V.1- 1946- Volume(issue)/page/year: 38,409,1965

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H317

[ Precautionary Statements ]:
P280-P301 + P310

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T: Toxic;

[ Risk Phrases ]:
R25

[ Safety Phrases ]:
S36/37/39-S45

[ RIDADR ]:
UN 2811 6.1/PG 3

[ WGK Germany ]:
3

[ RTECS ]:
NK6125000

[ Packaging Group ]:
III

[ Hazard Class ]:
6.1(b)

[ HS Code ]:
2914399090

Synthetic Route

Precursor & DownStream

Precursor

  • 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-6-(perfluorobutoxy)hexane
  • 2-(hydroxymethyl)-2-phenylindene-1,3-dione
  • 1,3-Indandione, 2-diazo-
  • benzene
  • 2-diazo-3-hydroxy-3-phenyl-1-indanone
  • (3-oxo-2-phenylinden-1-yl) thiocyanate
  • Phthalide
  • Benzaldehyde

DownStream

  • 1H-Indene-1,3(2H)-dione,2-(2-oxo-2-phenylethyl)-2-phenyl-
  • 3-anilino-2-phenylinden-1-one
  • 2-Phenylindene
  • 1H-Indene-1,3(2H)-dione,2-bromo-2-phenyl-
  • (2,2-BIINDAN)-1,1,3,3-TETRONE, 2,2-DIPHENYL-
  • 1H-Inden-1-one,3-(acetyloxy)-2-phenyl-
  • 2-Phenyl-isoindole-1,3-dione
  • benzoic acid
  • Diethyl phthalate
  • Phthalimide, N- (p-chlorophenyl)-

Customs

[ HS Code ]: 2914399090

[ Summary ]:
2914399090. other aromatic ketones without other oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:5.5%. General tariff:30.0%

Articles

Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Bioorg. Med. Chem. 18 , 2225-31, (2010)

There are many of pathogen parasite species with different susceptibility profile to antiparasitic drugs. Unfortunately, almost QSAR models predict the biological activity of drugs against only one pa...

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.

Toxicol. Mech. Methods 18 , 217-27, (2008)

ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes...

Maintenance of anticoagulant and antiplatelet agents for patients undergoing peribulbar anesthesia and vitreoretinal surgery.

Retina (Philadelphia, Pa.) 32(9) , 1868-73, (2012)

To establish the prevalence of anticoagulation (vitamin K antagonists) and antiplatelet agent therapy in patients undergoing vitreoretinal surgery and to compare the outcome of peribulbar anesthesia a...


More Articles


Related Compounds

  • Phenindione-d5
  • phenindione methyl ether
  • 4-Methyl-1-(pyrrolidin-2-yl)cyclohex-2-en-1-ol
  • 5-Fluoro-1-{8-hydroxyspiro[4.5]decan-6-yl}-1,2-dihydropyridin-2-one
  • 1-[(3-Chlorothiophen-2-yl)methyl]-4-methylcyclohex-2-en-1-ol
  • 1-Methyl-4-[(oxiran-2-yl)methyl]piperidine
  • 3-(3-bromo-1-methyl-1H-pyrazol-5-yl)-4-methylcyclohexan-1-amine
  • 4-Ethyl-3-phenylcyclohexan-1-amine
  • 4-Tert-butyl-3-(pyrrolidin-1-yl)cyclohexan-1-ol
  • 4-(1,2,3,4-Tetrahydroquinolin-4-yl)aniline
  • 4-(5-bromo-2-ethylcyclohexyl)-1-methyl-1H-1,2,3-triazole
  • 1-[(5-Bromopyridin-3-yl)sulfanyl]-4-methylpentan-2-one
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.